Stockscreener 앱 받기
5.23
4.56%
-0.25
시간 외 거래:
5.20
-0.03
-0.57%
전일 마감가:
$5.48
열려 있는:
$5.52
하루 거래량:
760.53K
Relative Volume:
0.48
시가총액:
$730.44M
수익:
$8.37M
순이익/손실:
$-69.66M
주가수익비율:
-9.3326
EPS:
-0.5604
순현금흐름:
$-51.45M
1주 성능:
-7.92%
1개월 성능:
+9.19%
6개월 성능:
+16.22%
1년 성능:
+211.31%
1일 변동 폭
$5.21
$5.54
1주일 범위
$5.21
$5.88
52주 변동 폭
$1.46
$5.88
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
5.23 | 730.44M | 8.37M | -69.66M | -51.45M | -0.5604 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 개시 | Oppenheimer | Outperform |
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACRS - TradingView
Piper Sandler Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS) - The Globe and Mail
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris - Barchart.com
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2000 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 3000E Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to book forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS) - TradingView
ACRS Forecast — Price Target — Prediction for 2027 - TradingView
ACRS Q1 2026 Earnings: Narrows Loss Per Share as Pre-Revenue Biotech Advances PipelineProfit Cycle Analysis - dars.gov.et
We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth - Moomoo
ACRS Q1 2026 Earnings: Slimmer Loss Beats Estimates as Stock ReboundsReturn On Capital - DonanımHaber
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
3 penny stocks under $5 backed by real revenue growth - MSN
Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aclaris Therapeutics Inc (ACRS) Institutional Confidence - TradingKey
Aclaris Therapeutics Inc (ACRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aclaris Therapeutics Inc (ACRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aclaris Therapeutics Inc (ACRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aclaris Therapeutics Inc (ACRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aclaris Therapeutics Inc (ACRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aclaris Therapeutics Holds Steady Near Support as Biotech Sector Watches Key LevelsMomentum Factor - newsline.com
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Aclaris Therapeutics (ACRS) Gains Analyst Attention as Stifel Flags Penny Stock OpportunityEarnings Revision Report - newsline.com
Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant - Stock Titan
Aclaris Therapeutics (ACRS) director gains new RSUs and stock options - Stock Titan
Stifel Raises Aclaris Therapeutics Price Target to Four Dollars - HarianBasis.co
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Insider Monkey
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052 - MSN
Aclaris Stockholders Approve Directors, Pay and Auditor - The Globe and Mail
Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC - Stock Titan
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Yahoo Finance
ACRS: All proposals passed, with no stockholder questions submitted during the meeting - TradingView
Q2 Earnings Forecast for ACRS Issued By Lifesci Capital - MarketBeat
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday - Benzinga
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital - Moomoo
ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform' - GuruFocus
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data - Bez Kabli
ACRSAclaris Therapeutics Inc Latest SEC Filings - Finviz
ACRS Q1 2026 Earnings: Smaller-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Acceleration Picks - newsline.com
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.46%
0.84%
자본화:
|
볼륨(24시간):